Celator Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting

SAN DIEGO & WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Celator Pharmaceuticals, a privately held company developing advanced therapies to treat cancer, and The Leukemia & Lymphoma Society (LLS) today announced positive clinical data in first relapse patients with acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. The findings of a randomized Phase 2b clinical study showed a statistically significant benefit in overall survival favoring CPX-351 in patients who had an unfavorable risk profile as assessed by the European Prognostic Index (EPI). In addition, positive trends were seen in overall patient survival, as well as complete remission rates, in patients treated with CPX-351 compared to salvage regimens. The clinical findings were presented this morning from the podium at the 53rd American Society of Hematology (ASH) Annual Meeting being held in San Diego, California (ASH Abstract #254).